Last updated on May 2018

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Clostridium Difficile Infection
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients 18 years of age or older with >3 unformed stools/24 hours with positive stool test for C. difficile.
  • Patients receiving 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of 5 days from the time of enrollment.

Exclusion Criteria:

  • Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon).
  • Patients with an allergy to oral vancomycin or fidaxomicin.
  • Patients anticipated to receive metronidazole after enrollment.
  • Patients who already received oral vancomycin or metronidazole (either oral or intravenous) for > 24 hours within the preceding 72 hours at the time of enrollment.
  • Patients anticipated to receive adjunctive C. difficile therapy (rifaxamin, nitazoxanide, tigecycline) after enrollment.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.